StocksMedium•5 November 2026•
1 min read
MetaVia’s DA-1726 Shows 68% Liver Fat Reduction in Phase 1 Trial
Key Facts
1DA-1726 demonstrated a 68% reduction in liver fat and a 13.5% placebo-adjusted weight loss in Phase 1 interim data.
MetaVia Inc. announced positive interim results from Part 3B of its Phase 1 trial for DA-1726, which demonstrated a 68% reduction in liver fat. PR Newswire reported that the drug also achieved a 13.5% placebo-adjusted weight loss, highlighting its potential efficacy in treating obesity and liver-related conditions.
The data supports the advancement of DA-1726 into a Phase 2 study for MetALD and ALD, currently targeted for the second half of 2027. MTVA closed at $1.34 on November 4, 2026, having reached a day high of $1.45 and a low of $1.26 during that session.